サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1787200

マルチオミクスの世界市場

Multiomics

出版日
ページ情報
英文 209 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
マルチオミクスの世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 209 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のマルチオミクスの市場規模は2030年までに74億米ドルに達する見込み

世界のマルチオミクスの市場規模は、2024年に29億米ドルと推定され、2024年～2030年にCAGR16.6%で成長し、2030年には74億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるバルクマルチオミクスは、CAGR17.9%を記録し、分析期間終了時には51億米ドルに達すると予測されます。シングルセルマルチオミクスセグメントの成長率は、分析期間のCAGRで14.1％と推定されています。

米国市場は7億6,910万米ドルと推定、中国はCAGR15.6％で成長予測

米国のマルチオミクス市場は、2024年に7億6,910万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024～2030年のCAGRは15.6%です。その他の注目すべき地域市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ15.5％と14.2％と予測されています。欧州では、ドイツがCAGR約12.1%で成長すると予測されています。

世界のマルチオミクス市場：主要動向と促進要因の概要

マルチオミクスはバイオロジカルインサイトと精密医療をどのように再定義しているか？

ゲノミクス、トランスクリプトミクス、プロテオミクス、エピゲノミクス、メタボロミクスを組み合わせた統合的アプローチであるマルチオミクスは、生物学調査と臨床応用に革命をもたらしています。複数の生物層にまたがる膨大なデータセットを活用することで、マルチオミクスは複雑な疾患、生物学的機能、個別化医療に対するより深い理解を提供します。シーケンス技術とハイスループット分析ツールの進歩により、研究者はさまざまな分子成分間の相互作用をかつてない精度で調査できるようになりました。機械学習と人工知能の統合により、マルチオミクスデータの解釈はさらに加速され、バイオマーカー発見、疾病診断、治療介入の飛躍的進歩につながっています。腫瘍学では、マルチオミクスは腫瘍の不均一性を明らかにし、より的を絞った治療レジメンを促進しています。同様に、アルツハイマー病やパーキンソン病などの神経変性疾患においても、マルチオミクスは遺伝的・代謝的背景を明らかにするシステム生物学的アプローチを可能にします。製薬業界では、創薬の強化、臨床試験の層別化の最適化、治療に対する患者の反応を予測するためにマルチオミクスを積極的に採用しています。クラウドコンピューティングと高度なバイオインフォマティクスツールの出現により、マルチオミクスデータを大規模に保存、分析、解釈する能力が大幅に向上し、世界中の研究者がよりアクセスしやすくなりました。政府やヘルスケア機関は、トランスレーショナルリサーチを加速する可能性を認識し、大規模なマルチオミクスイニシアチブに資金を提供するようになってきています。このような進歩にもかかわらず、この分野はデータの調和、標準化、データ共有における倫理的配慮に関する課題に直面しています。とはいえ、計算生物学とデータ統合フレームワークの絶え間ない革新により、マルチオミクスは精密医療と疾病予防戦略を変革する態勢を整えています。

マルチオミクスの恩恵を受ける新しい用途と産業とは？

マルチオミクスは、精密医療における役割以外にも、農業、マイクロバイオーム研究、栄養科学、環境モニタリングなど、様々な分野で応用されています。農業分野では、マルチオミクスは作物の回復力を高め、土壌マイクロバイオームを改善し、気候変動によるストレス要因に耐えられる遺伝的に優れた植物品種を開発するために採用されています。マイクロバイオーム研究は、人間の健康、農業、産業バイオテクノロジーにおける複雑な微生物相互作用の研究にマルチオミクスを活用しています。メタゲノミクス、プロテオミクス、メタボロミクスを腸内細菌叢研究に応用することで、マイクロバイオームの構成と肥満、糖尿病、炎症性疾患などの疾患とを関連付ける画期的な発見がなされました。栄養科学では、マルチオミクスがニュートリゲノミクスへの道を開いており、個人の遺伝的・代謝的プロファイルに基づいてパーソナライズされた食事の推奨が行われています。飲食品業界では、発酵プロセスの最適化、プロバイオティクスの処方改善、高度な微生物プロファイリングによる食品の安全性確保にマルチオミクスが活用されています。また、マルチオミクスは、生態系の生物多様性のモニタリング、汚染の影響の追跡、深海熱水噴出孔のような極限環境における微生物群集の調査などを可能にし、環境科学にも大きく貢献しています。毒物学の分野では、化学物質の曝露を分子レベルで理解するためにマルチオミクスのアプローチがますます統合され、リスク評価や規制の枠組みが改善されつつあります。合成生物学の進歩に伴い、マルチオミクスは新規バイオマテリアル、バイオ燃料、バイオ医薬品の工学化を促進し、その産業的意義をさらに拡大しています。マルチオミクスの学際的な採用が増加していることは、従来の生物医学研究の枠を超えたイノベーションを推進し、科学的および商業的な部門に変革をもたらすインパクトを強調しています。

なぜマルチオミクスデータ統合が将来の科学的ブレークスルーに不可欠なのか？

マルチオミクスデータセットの統合は、この分野で最も課題的でありながら将来性のある課題の1つです。マルチオミクス研究から生成される膨大な量のデータには、異なる生物学的レイヤーを横断して洞察を統合できる高度な計算モデルが必要です。AI主導の分析、連携学習、ネットワークベースのモデリングにおける最近の進歩は、マルチオミクスデータ融合を改善し、よりロバストなバイオマーカー発見と疾患モデリングにつながっています。データパイプラインの標準化とオープンアクセスリポジトリの開発により、研究者間の共同研究が促進され、メタアナリシスや集団横断的研究が可能になりました。シングルセルマルチオミクスの出現は、細胞の不均一性を理解する解像度をさらに高め、免疫学、がん生物学、発生生物学において有用であることを証明しています。Spatialマルチオミクスはもう一つの画期的な技術であり、研究者が組織内の分子間相互作用を空間的に正確にマッピングすることを可能にし、疾患病理学に新たな洞察を提供します。しかし、バッチ効果、再現性の問題、計算基盤の強化の必要性などの課題が、依然として普及の障壁となっています。多施設共同研究やデータ共有の枠組みを推進することで、これらの課題を軽減し、マルチオミクス調査の再現性と透明性を高めることが期待されます。マルチオミクスと、計算モデルが生物学的反応をシミュレートするデジタルツインテクノロジーとの統合も、個別化医療や治療開発に革命をもたらす可能性のある有望なフロンティアです。マルチオミクスが進化し続けるにつれて、量子コンピューター、CRISPRを用いたゲノム編集、バイオプリンティングなどの最先端分野との交わりも増え、科学的発見に新たな道が開かれつつあります。マルチオミクスデータをシームレスに統合する能力は、この技術の可能性を最大限に引き出し、病気の軌跡や治療反応のより正確な予測を可能にする上で極めて重要です。

マルチオミクスの世界市場急成長の促進要因は？

世界のマルチオミクス市場の成長は、技術の進歩、創薬における採用の増加、オミックスベースの研究に対する資金提供の増加など、いくつかの要因によってもたらされています。次世代シーケンシング（NGS）、質量分析、ハイスループットスクリーニングプラットフォームの急速な開発により、精度と拡張性が向上する一方でコストが大幅に削減されました。製薬業界やバイオテクノロジー業界は、精密医療イニシアチブを加速し、バイオマーカー同定を強化し、臨床試験の患者選択を最適化するために、マルチオミクスに多額の投資を行っています。がん、自己免疫疾患、神経変性疾患などの複雑な疾患の発生率が増加しているため、マルチオミクスを活用した診断薬や治療薬の需要がさらに高まっています。マルチオミクスを人工知能やビッグデータ解析と統合することで、特に希少疾患や個別化ヘルスケアソリューションに焦点を当てた研究に、ベンチャーキャピタルや政府から多額の資金が集まっています。規制機関は、医薬品の安全性と有効性を向上させるマルチオミクスの価値をますます認識し、オミックスベースの臨床試験やコンパニオン診断を支援する有利な政策につながっています。消費者向け遺伝子検査会社や個別化された健康プログラムの台頭は、マルチオミクス用途の商業的展望をさらに広げています。さらに、農業、食品安全、環境モニタリングにおけるマルチオミクスの重視の高まりは、ヒトの健康以外の分野でのマルチオミクスの採用を促進し、市場の多様化に寄与しています。データ解析、バイオマーカー検証、クラウドベースのインフォマティクスプラットフォームなど、エンドツーエンドのソリューションを提供するマルチオミクスサービス提供者の出現により、マルチオミクス研究は学術研究者にとっても産業研究者にとってもより身近なものとなっています。マルチオミクス技術開発者、ヘルスケア提供者、製薬会社間の戦略的パートナーシップは、イノベーションを促進し、商業化を加速し、トランスレーショナルリサーチの取り組みを強化しています。世界のヘルスケア産業が予防的で精密な治療モデルへとシフトする中、マルチオミクスは将来のヘルスケアパラダイムにおいて不可欠なツールとなると思われます。マルチオミクス技術の絶え間ない進歩と、多業種にわたる用途の増加により、市場は今後数年で飛躍的な成長を遂げる見込みです。

セグメント

製品タイプ（バルクマルチオミクス、シングルセルマルチオミクス）、プラットフォームタイプ（ゲノミクスプラットフォーム、トランスクリプトミクスプラットフォーム、プロテオミクスプラットフォーム、メタボロミクスプラットフォーム、統合オミクスプラットフォーム）、用途（腫瘍学用途、細胞生物学用途、神経学用途、免疫学用途）、最終用途（学術・研究機関最終用途、製薬・バイオテクノロジー企業最終用途、その他最終用途）

調査対象企業の例

  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Aitia（前GNS Healthcare）
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Freenome Holdings, Inc.
  • Human Longevity, Inc.
  • Illumina, Inc.
  • Mission Bio, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer, Inc.
  • Pleno, Inc.
  • Psomagen, Inc.
  • QIAGEN N.V.
  • Shimadzu Corporation
  • SOPHiA GENETICS
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

一般的に行われているLLMや業界特化型SLMへのクエリに頼るのではなく、私たちは世界中のドメイン専門家によって精選されたコンテンツを集約したリポジトリを構築しました。その中には、動画の文字起こし、ブログ、検索エンジンを用いた調査、さらには膨大な企業データ、製品・サービス情報、市場データが含まれています。

関税影響係数

私たちは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32255

Global Multiomics Market to Reach US$7.4 Billion by 2030

The global market for Multiomics estimated at US$2.9 Billion in the year 2024, is expected to reach US$7.4 Billion by 2030, growing at a CAGR of 16.6% over the analysis period 2024-2030. Bulk Multiomics, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Single-Cell Multiomics segment is estimated at 14.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$769.1 Million While China is Forecast to Grow at 15.6% CAGR

The Multiomics market in the U.S. is estimated at US$769.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 15.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.5% and 14.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Multiomics Market - Key Trends & Drivers Summarized

How Is Multiomics Redefining Biological Insights and Precision Medicine?

Multiomics, an integrative approach combining genomics, transcriptomics, proteomics, epigenomics, and metabolomics, is revolutionizing biological research and clinical applications. By leveraging vast datasets across multiple biological layers, multiomics offers a deeper understanding of complex diseases, biological functions, and personalized medicine. Advances in sequencing technologies and high-throughput analytical tools have enabled researchers to study interactions between different molecular components with unprecedented precision. The integration of machine learning and artificial intelligence has further accelerated the interpretation of multiomics data, leading to breakthroughs in biomarker discovery, disease diagnostics, and therapeutic interventions. In oncology, multiomics is uncovering tumor heterogeneity and facilitating more targeted treatment regimens. Similarly, in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, multiomics enables a systems biology approach to uncover genetic and metabolic underpinnings. The pharmaceutical industry is actively adopting multiomics to enhance drug discovery, optimize clinical trial stratification, and predict patient responses to therapies. The advent of cloud computing and advanced bioinformatics tools has significantly improved the ability to store, analyze, and interpret multiomics data at scale, making it more accessible to researchers worldwide. Governments and healthcare institutions are increasingly funding large-scale multiomics initiatives, recognizing their potential to accelerate translational research. Despite these advancements, the field faces challenges related to data harmonization, standardization, and ethical considerations in data sharing. Nevertheless, with continuous innovation in computational biology and data integration frameworks, multiomics is poised to transform precision medicine and disease prevention strategies.

What Are the Emerging Applications and Industries Benefiting from Multiomics?

Beyond its role in precision medicine, multiomics is finding applications in diverse fields, including agriculture, microbiome research, nutrition science, and environmental monitoring. In agriculture, multiomics is being employed to enhance crop resilience, improve soil microbiomes, and develop genetically superior plant varieties that can withstand climate change-induced stressors. Microbiome research is leveraging multiomics to study complex microbial interactions in human health, agriculture, and industrial biotechnology. The application of metagenomics, proteomics, and metabolomics in gut microbiota studies has led to groundbreaking discoveries linking microbiome composition to diseases such as obesity, diabetes, and inflammatory disorders. In nutrition science, multiomics is paving the way for nutrigenomics, where personalized dietary recommendations are tailored based on an individual’s genetic and metabolic profile. The food and beverage industry is utilizing multiomics to optimize fermentation processes, improve probiotic formulations, and ensure food safety through advanced microbial profiling. Multiomics is also making significant contributions to environmental sciences by enabling researchers to monitor ecosystem biodiversity, track pollution effects, and study microbial communities in extreme environments such as deep-sea hydrothermal vents. The field of toxicology is increasingly integrating multiomics approaches to understand chemical exposures at the molecular level, improving risk assessments and regulatory frameworks. With advancements in synthetic biology, multiomics is facilitating the engineering of novel biomaterials, biofuels, and biopharmaceuticals, further expanding its industrial significance. The increasing interdisciplinary adoption of multiomics underscores its transformative impact across scientific and commercial sectors, driving innovation beyond traditional biomedical research.

Why Is Multiomics Data Integration Critical for Future Scientific Breakthroughs?

The integration of multiomics datasets remains one of the most challenging yet promising aspects of the field. The vast volume of data generated from multiomics studies requires sophisticated computational models capable of synthesizing insights across different biological layers. Recent advancements in AI-driven analytics, federated learning, and network-based modeling have improved multiomics data fusion, leading to more robust biomarker discovery and disease modeling. The standardization of data pipelines and the development of open-access repositories have facilitated greater collaboration among researchers, allowing for meta-analyses and cross-population studies. The emergence of single-cell multiomics has further enhanced resolution in understanding cellular heterogeneity, proving valuable in immunology, cancer biology, and developmental biology. Spatial multiomics is another breakthrough, enabling researchers to map molecular interactions within tissues with spatial precision, offering new insights into disease pathology. However, challenges such as batch effects, reproducibility issues, and the need for enhanced computational infrastructure remain barriers to widespread adoption. The push towards multi-institutional collaborations and data-sharing frameworks is expected to mitigate these challenges, fostering greater reproducibility and transparency in multiomics research. The integration of multiomics with digital twin technologies, where computational models simulate biological responses, is another promising frontier that could revolutionize personalized medicine and therapeutic development. As multiomics continues to evolve, it is increasingly intersecting with other cutting-edge fields such as quantum computing, CRISPR-based genome editing, and bioprinting, opening new avenues for scientific discovery. The ability to seamlessly integrate multiomics data will be crucial in unlocking the full potential of this technology, enabling more accurate predictions of disease trajectories and treatment responses.

What Is Driving the Rapid Growth of the Global Multiomics Market?

The growth in the global multiomics market is driven by several factors, including technological advancements, rising adoption in drug discovery, and increased funding for omics-based research. The rapid development of next-generation sequencing (NGS), mass spectrometry, and high-throughput screening platforms has significantly reduced costs while improving accuracy and scalability. The pharmaceutical and biotechnology industries are heavily investing in multiomics to accelerate precision medicine initiatives, enhance biomarker identification, and optimize clinical trial patient selection. The increasing incidence of complex diseases, including cancer, autoimmune disorders, and neurodegenerative conditions, is further fueling demand for multiomics-driven diagnostics and therapeutics. The integration of multiomics with artificial intelligence and big data analytics is attracting substantial venture capital and government funding, particularly for research focused on rare diseases and personalized healthcare solutions. Regulatory agencies are increasingly recognizing the value of multiomics in improving drug safety and efficacy, leading to favorable policies supporting omics-based clinical trials and companion diagnostics. The rise of direct-to-consumer genetic testing companies and personalized wellness programs is further expanding the commercial landscape for multiomics applications. Moreover, the growing emphasis on multiomics in agriculture, food safety, and environmental monitoring is driving its adoption beyond human health, contributing to market diversification. The emergence of multiomics service providers offering end-to-end solutions, including data analysis, biomarker validation, and cloud-based informatics platforms, is making multiomics research more accessible to academic and industrial researchers alike. Strategic partnerships between multiomics technology developers, healthcare providers, and pharmaceutical companies are fostering innovation, accelerating commercialization, and enhancing translational research efforts. As the global healthcare industry shifts towards preventive and precision-based treatment models, multiomics is set to become an indispensable tool in future healthcare paradigms. With continuous advancements in multiomics technologies and their increasing applications across multiple industries, the market is poised for exponential growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Multiomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Bulk Multiomics, Single-Cell Multiomics); Platform Type (Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform, Integrated Omics Platforms); Application (Oncology Application, Cell Biology Application, Neurology Application, Immunology Application); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Aitia (formerly GNS Healthcare)
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Freenome Holdings, Inc.
  • Human Longevity, Inc.
  • Illumina, Inc.
  • Mission Bio, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer, Inc.
  • Pleno, Inc.
  • Psomagen, Inc.
  • QIAGEN N.V.
  • Shimadzu Corporation
  • SOPHiA GENETICS
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Multiomics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Integration of Multiomics Data Sets Strengthens the Business Case for Precision Medicine
    • Rising Focus on Systems Biology Propels Growth in Multiomics Research
    • Increasing Adoption of Personalized Healthcare Expands the Addressable Market Opportunity
    • Convergence of Genomics, Proteomics, and Metabolomics Accelerates Demand for Integrated Platforms
    • Big Data and AI Capabilities Drive Adoption of Multiomics Analytics
    • Growing Investments in Life Sciences R&D Sustain Growth Momentum
    • Clinical Trials Leveraging Multiomics Approaches Generate New Opportunities in Drug Discovery
    • Advances in Single-Cell Sequencing Technologies Drive Demand for High-Resolution Multiomics
    • Expansion of Population-Scale Biobanking Initiatives Spurs Adoption of Multiomics Technologies
    • Strategic Collaborations Between Biotech and Tech Firms Boost Commercialization Potential
    • Decentralization of Diagnostic Workflows Drives Demand for Scalable Multiomics Platforms
    • Rising Prevalence of Chronic and Complex Diseases Throws the Spotlight on Omics-Based Biomarker Discovery
    • Increased Regulatory Support for Genomic Testing Strengthens the Reimbursement Framework for Multiomics
    • Development of Multiomic Diagnostic Kits Generates Opportunities for Point-of-Care Applications
    • Integration with Electronic Health Records Drives Clinical Utility and Adoption in Hospitals
    • Emergence of Cloud-Native Platforms Expands Accessibility and Scalability for Multiomics Data Processing
    • Improved Cost-Efficiency of Sequencing Technologies Drives Market Penetration in Developing Economies
    • Rising Academic and Government Funding Accelerates Translational Research in Multiomics
    • Growing Emphasis on Real-Time Disease Monitoring Supports Growth of Longitudinal Multiomics Studies
    • Standardization and Interoperability Challenges Create Barriers but Also Spur Innovation in Unified Analytics Frameworks
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multiomics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multiomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Multiomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Bulk Multiomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Bulk Multiomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Single-Cell Multiomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Single-Cell Multiomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Immunology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Immunology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cell Biology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Cell Biology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Genomics Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Genomics Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Transcriptomics Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Transcriptomics Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Proteomics Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Proteomics Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Metabolomics Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Metabolomics Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Integrated Omics Platforms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Integrated Omics Platforms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • JAPAN
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • CHINA
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • EUROPE
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Multiomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Multiomics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • FRANCE
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • GERMANY
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • UNITED KINGDOM
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030

IV. COMPETITION